welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Novo Biosciences achieves major milestones in moving trodusquemine into clinical trials
Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy (DMD). Trodusquemine is a repurposed drug candidate that has already been shown to be well tolerated by patients.
“Trodusquemine holds significant potential for the treatment of some of our most devastating diseases,” said Kevin Strange, Ph.D., Novo’s CEO. “Our recent progress on the path toward clinical trials gives hope to the millions of patients who face limited treatment options.”
rareRelated
-
Study of DS-5141b in Patients With Duchenne Muscular DystrophyThis is a phase I/II study to evaluate t...
-
UT Researcher, With CureDuchenne Support, Launches Company to Treat DMD Using CRISPR/Cas9 TechnologyEric Olson, a molecular biologist, has s...
-
Duchenne Muscular Dystrophy < 18y in Norway: Genotype/Phenotype, Growth, Puberty, Bone Health and Quality of LifeThe study will give a consent based epid...
-
A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocortico...The purpose of the study is to assess th...
-
Clinical trial shows some promise for Duchenne muscular dystrophy drugThe results of an international clinical...
-
Extension Study of ACE-031 in Subjects With Duchenne Muscular DystrophyTo evaluate the long-term safety and tol...
-
DMD clinical therapies II: P.133 The burden of participation in a clinical trial for boys with Duchenne muscular dys...Despite some medical breakthroughs in Du...
-
Gene Therapy for Duchenne Muscular DystrophyGene Therapy for Duchenne Muscular Dyst...
-
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two ...PTC Therapeutics, Inc. today announced t...
